Celgene Chairman Bob Hugin handed the CEO baton to Mark Alles in 2016, but he retained serious influence at the company—and in the biotech industry overall. Now, he's bidding goodbye to the company he joined 19 years ago. Up next? Maybe a run for the Senate.Original Article
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
